Full Transcript: Aytu BioPharma Q2 2026 Earnings Callby Benzinga Insights Benzinga Staff WriterFollowArticleFeaturedTickersList12345!!!Aytu BioPharma (NASDAQ:AYTU) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below.This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/.The full earnings call is available at https://www.webcaster5.com/Webcast/Page/2142/53322Full Transcri ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

分组1 - Aytu BioPharma Inc. reported a quarterly loss of $1.05 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.26, marking an earnings surprise of -303.85% [1] - The company posted revenues of $15.17 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 26.27%, although this represents a decline from year-ago revenues of $16.22 million [2] - Aytu BioPharma shares have increased by approximately 4.2% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.10 on revenues of $12.7 million, and for the current fiscal year, it is -$0.54 on revenues of $52.63 million [7] - The Medical - Biomedical and Genetics industry, to which Aytu BioPharma belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Illumina, is expected to report quarterly earnings of $1.26 per share, reflecting a year-over-year increase of 46.5%, with revenues projected at $1.16 billion, up 4.6% from the previous year [9][10]

Aytu Biopharma (NasdaqCM:AYTU) Q2 2026 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsJosh Disbrow - Co-Founder, CEO, and DirectorRobert Blum - Managing PartnerRyan Selhorn - CFOConference Call ParticipantsEd Woo - Senior Research AnalystNaz Rahman - Senior Biotechnology Research AnalystThomas Flaten - Senior Research AnalystOperatorGood day, everyone, and welcome to the Aytu BioPharma Fiscal 2026 second quarter earnings call. At this time, all participants are placed on a listen-only mode, ...

Aytu Biopharma (NasdaqCM:AYTU) Q2 2026 Earnings call February 03, 2026 04:30 PM ET Company ParticipantsJosh Disbrow - Co-Founder, CEO, and DirectorRobert Blum - Managing PartnerRyan Selhorn - CFOConference Call ParticipantsEd Woo - Senior Research AnalystNaz Rahman - Senior Biotechnology Research AnalystThomas Flaten - Senior Research AnalystOperatorGood day, everyone, and welcome to the Aytu BioPharma Fiscal 2026 second quarter earnings call. At this time, all participants are placed on a listen-only mode, ...

Aytu Biopharma (NasdaqCM:AYTU) Q2 2026 Earnings call February 03, 2026 04:30 PM ET Speaker2Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2026 second quarter earnings call. At this time, all participants are placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation. It is now my pleasure to hand the floor over to your host, Robert Blum. Sir, the floor is yours.Speaker3All right. Thank you very much, and, good afternoon, everyone. As the ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ___________ Commission File Number: 001-38247 AYTU BIOPHARMA, INC. (Exact name of registrant as specified in its charter) | Delaware | 47-0883144 | | -- ...

Exhibit 99.1 Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUA™ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host confer ...

Total net revenue of $15.2 million Adjusted EBITDA1 of $(0.8) million, which includes EXXUA launch investments $30.0 million cash balance at December 31, 2025 Company launched EXXUAâ"¢ (gepirone) extended-release tablets ("EXXUA") in December 2025 as the centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market Company to host conference call and webcast today, February 3, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Ne ...

Medicines Made for Life Nasdaq: AYTU February 2026 Actor portrayals. Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the futu ...